title: Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
abstract: In January 2014, the US Food and Drug Administration approved tasimelteon (Hetlioz™), a melatonin-receptor agonist for the treatment of non-24-hour sleep-wake disorder. This article provides an overview of the mechanism of action, pharmacokinetic properties, as well as the clinical efficacy, safety, and tolerability of tasimelteon. Relevant information was identified through a comprehensive literature search of several databases using the key words tasimelteon, Non-24-hour Sleep-Wake disorder, Non-24, and melatonin. Further information was obtained from the tasimelteon package insert, fda.gov, clinicaltrials.gov, briefing materials provided by Vanda Pharmaceuticals, and posters from scientific meetings.
authors.affiliation: St John Fisher College Wegmans School of Pharmacy, Rochester, NY, USA jmb1690@yahoo.com.
authors.forename: Janene M
authors.initials: JM
authors.lastname: Bonacci
authors.affiliation: Center for Primary Care, University of Rochester Medical Center, Rochester, NY, USA.
authors.forename: Jineane V
authors.initials: JV
authors.lastname: Venci
authors.affiliation: St John Fisher College Wegmans School of Pharmacy, Rochester, NY, USA.
authors.forename: Mona A
authors.initials: MA
authors.lastname: Gandhi
mesh_terms: D001572:Benzofurans / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D003521:Cyclopropanes / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D044094:Receptors, Melatonin / Q000819:agonists*; D020178:Sleep Disorders, Circadian Rhythm / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D001572:Benzofurans; D003521:Cyclopropanes; D044094:Receptors, Melatonin; C478745:tasimelteon
keywords: VEC-162; hetlioz; melatonin-receptor agonist; non-24-hour sleep–wake disorder; tasimelteon